BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) and Organon & Co. (NYSE:OGN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Insider and Institutional Ownership
18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for BioNexus Gene Lab and Organon & Co., as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioNexus Gene Lab | 1 | 0 | 0 | 0 | 1.00 |
| Organon & Co. | 2 | 5 | 0 | 0 | 1.71 |
Volatility & Risk
BioNexus Gene Lab has a beta of 4.06, indicating that its stock price is 306% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.
Profitability
This table compares BioNexus Gene Lab and Organon & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioNexus Gene Lab | -54.70% | -37.43% | -32.88% |
| Organon & Co. | 3.99% | 99.95% | 6.22% |
Valuation and Earnings
This table compares BioNexus Gene Lab and Organon & Co.”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioNexus Gene Lab | $7.43 million | 0.66 | -$2.98 million | ($1.48) | -1.38 |
| Organon & Co. | $6.22 billion | 0.57 | $187.00 million | $0.93 | 14.52 |
Organon & Co. has higher revenue and earnings than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Summary
Organon & Co. beats BioNexus Gene Lab on 11 of the 13 factors compared between the two stocks.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
About Organon & Co.
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
